PubRank

Michael T Hemann

Author PubWeight™ 102.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A microRNA polycistron as a potential human oncogene. Nature 2005 40.21
2 Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007 12.42
3 Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005 8.99
4 Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010 3.03
5 DNA damage-mediated induction of a chemoresistant niche. Cell 2010 2.94
6 Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov 2013 2.59
7 The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009 2.56
8 Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009 2.54
9 Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008 2.53
10 In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet 2009 1.99
11 Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A 2010 1.95
12 Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A 2010 1.85
13 Genes and transposons are differentially methylated in plants, but not in mammals. Genome Res 2003 1.66
14 Haploinsufficiency of mTR results in defects in telomere elongation. Proc Natl Acad Sci U S A 2002 1.56
15 Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 2004 1.46
16 Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009 1.44
17 A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 2010 1.26
18 Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A 2012 1.19
19 Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res 2003 1.17
20 A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep 2005 1.09
21 Chemotherapeutic resistance: surviving stressful situations. Cancer Res 2011 0.99
22 Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. J Am Chem Soc 2013 0.91
23 Understanding resistance to combination chemotherapy. Drug Resist Updat 2012 0.88
24 Nek4 status differentially alters sensitivity to distinct microtubule poisons. Cancer Res 2010 0.88
25 Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev 2012 0.88
26 Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther 2009 0.84
27 Necroptosis-inducing rhenium(V) oxo complexes. J Am Chem Soc 2015 0.83
28 Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst 2013 0.82
29 Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Res 2011 0.82
30 A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. J Am Chem Soc 2014 0.81
31 Integrated network analyses for functional genomic studies in cancer. Semin Cancer Biol 2013 0.80
32 Unraveling tumor suppressor networks with in vivo RNAi. Cell Stem Cell 2013 0.76
33 The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles. Dalton Trans 2016 0.75
34 Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy". J Am Chem Soc 2016 0.75
35 A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cancer Cell 2015 0.75